Lexicon Pharmaceuticals Files 8-K on Financials

Ticker: LXRX · Form: 8-K · Filed: Aug 6, 2025

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: LXRX

TL;DR

LEXICON filed an 8-K on Aug 6, 2025, updating financials. Details to follow.

AI Summary

Lexicon Pharmaceuticals, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending August 6, 2025. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This 8-K filing indicates Lexicon Pharmaceuticals is providing an update on its financial condition and operational results to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not inherently indicate new risks.

Key Players & Entities

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided excerpt does not contain specific financial figures or operational details, only that the filing pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

What is the filing date and the period of report for this 8-K?

The filing date is August 6, 2025, and the conformed period of report is also August 6, 2025.

What is the primary business of Lexicon Pharmaceuticals, Inc. according to the filing?

Lexicon Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

Where are Lexicon Pharmaceuticals, Inc.'s principal executive offices located?

The principal executive offices are located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.

What is the SEC file number for Lexicon Pharmaceuticals, Inc.?

The SEC file number for Lexicon Pharmaceuticals, Inc. is 000-30111.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding LEXICON PHARMACEUTICALS, INC. (LXRX).

View full filing on EDGAR

View on Read The Filing